Keyphrases
Structural Investigation
100%
HERG1
100%
Pore Domain
100%
Inactivated State
100%
Vesnarinone
100%
K Channels
100%
Ether
75%
Phosphodiesterase 3 (PDE3)
75%
Principal Coordinate Analysis (PCoA)
25%
Area Calculation
25%
Binding Energy
25%
Amino Acid Residues
25%
Channel Model
25%
Computational Approach
25%
Molecular Docking
25%
MM-PBSA
25%
In Silico Methods
25%
Binding Mechanism
25%
K+ Channels
25%
Long QT Syndrome
25%
Channel Dynamics
25%
Cyclic Adenosine Monophosphate (cAMP)
25%
Intracellular Messenger
25%
Cyclic GMP
25%
Torsades Des Pointes
25%
Pattern Evaluation
25%
Time Evaluation
25%
Binding Times
25%
Energy Decomposition Analysis
25%
Cardiotonic Agents
25%
Adenosine 3′
25%
Life-threatening Arrhythmias
25%
Docking Molecular Dynamics Simulations
25%
Intracellular Concentration
25%
Binding Pattern
25%
Drug Interactions
25%
Biochemistry, Genetics and Molecular Biology
Dynamics
100%
Phosphodiesterase 3
100%
Potassium Channel
100%
Enzyme
66%
Docking (Molecular)
66%
Amino Acids
33%
Principal Component Analysis
33%
Second Messenger System
33%
Surface Area
33%
Torsades De Pointes
33%
Drug Interaction
33%
Binding Energy
33%
Cyclic Adenosine Monophosphate
33%
Cyclic Guanosine Monophosphate
33%
Cardiac Dysrhythmia
33%
Long QT Syndrome
33%
Neuroscience
Phosphodiesterase III
100%
Potassium Channel
100%
Cyclic Guanosine Monophosphate
50%
Cyclic Adenosine Monophosphate
50%
Amino Acid
50%
Molecular Docking
50%
Second Messenger System
50%
Cardiac Stimulant
50%
PDE3 Inhibitor
50%
Cardiac Dysrhythmia
50%
Long QT Syndrome
50%
Chemistry
Potassium Ion
100%
Cyclic Guanosine Monophosphate
50%
Cyclic Adenosine Monophosphate
50%
Cardiotonic Agent
50%
Drug Residue
50%
Surface Area
50%
Binding Energy
50%
Amino Acid
50%
Boltzmann Equation
50%
Pharmacology, Toxicology and Pharmaceutical Science
Piperanometozine
100%
Potassium Channel
100%
Phosphodiesterase III
50%
Amino Acid
25%
Cyclic AMP
25%
Cyclic GMP
25%
Heart Arrhythmia
25%
Phosphodiesterase III Inhibitor
25%
Cardiotonic Agent
25%
Torsade Des Pointes
25%
Long QT Syndrome
25%
Drug Interaction
25%